Aneuploidies are major causes of perinatal death and childhood handicap; maternal serum screening test is effective screening method for detection of major aneuploidies (Trisomy 21 & Trisomy 18/13) in the first trimester of pregnancy. Screening by a combination of fetal nuchal translucency and maternal serum free-β-human chorionic gonadotrophin & pregnancy-associated plasma protein-A can identify about 90% of fetuses with trisomy 21 and other major aneuploidies for a false-positive rate of 5%. The performance of first-trimester screening is further improved by inclusion of the nasal bone and flow in the ductus venosus & across the tricuspid valve in the risk assessment.

  • Test Type:
  • Pre-test Information:
    Biochemical risk valid between 9-13+6 weeks gestation and combined risk assessment is valid between 11-13+6 weeks gestation as per USG. Provide maternal Date of birth (dd/mm/yy); Number of Fetuses (Single/Twins); Diabetic status and Body Weight in Kg, IVF, Smoking & Previous history of Trisomy 21 pregnancy in Maternal Serum Screen Form (Form 11) and Ultrasound (USG is mandatory).
  • Report Delivery:
    Sample by Tues / Thu / Sat 9 am; Report same day
  • Components:

Sample Report